CoMFA/CoMSIA 3D-QSAR of pyrimidine inhibitors of Pneumocystis carinii dihydrofolate reductase. 2012

Osvaldo A Santos-Filho, and Delphine Forge, and Lucas V B Hoelz, and Guilherme B L de Freitas, and Thiago O Marinho, and Jocley Q Araújo, and Magaly G Albuquerque, and Ricardo B de Alencastro, and Nubia Boechat
Laboratório de Modelagem Molecular, Departamento de Síntese Orgânica, Instituto de Tecnologia em Fármacos, Fundação Oswaldo Cruz, Rua Sizenando Nabuco, 100, Manguinhos, 21041-250, Rio de Janeiro, RJ, Brazil. osvaldofilho@far.fiocruz.br

Pneumocystis carinii is typically a non-pathogenic fungus found in the respiratory tract of healthy humans. However, it may cause P. carinii pneumonia (PCP) in people with immune deficiency, affecting mainly premature babies, cancer patients and transplant recipients, and people with acquired immunodeficiency syndrome (AIDS). In the latter group, PCP occurs in approximately 80% of patients, a major cause of death. Currently, there are many available therapies to treat PCP patients, including P. carinii dihydrofolate reductase (PcDHFR) inhibitors, such as trimetrexate (TMX), piritrexim (PTX), trimethoprim (TMP), and pyrimethamine (PMT). Nevertheless, the high percentage of adverse side effects and the limited therapeutic success of the current drug therapy justify the search for new drugs rationally planned against PCP. This work focuses on the study of pyrimidine inhibitors of PcDHFR, using both CoMFA and CoMSIA 3D-QSAR methods.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D005493 Folic Acid Antagonists Inhibitors of the enzyme, dihydrofolate reductase (TETRAHYDROFOLATE DEHYDROGENASE), which converts dihydrofolate (FH2) to tetrahydrofolate (FH4). They are frequently used in cancer chemotherapy. (From AMA, Drug Evaluations Annual, 1994, p2033) Antifolate,Antifolates,Dihydrofolate Reductase Inhibitor,Folic Acid Antagonist,Dihydrofolate Reductase Inhibitors,Folic Acid Metabolism Inhibitors,Acid Antagonist, Folic,Acid Antagonists, Folic,Antagonist, Folic Acid,Antagonists, Folic Acid,Inhibitor, Dihydrofolate Reductase,Inhibitors, Dihydrofolate Reductase,Reductase Inhibitor, Dihydrofolate,Reductase Inhibitors, Dihydrofolate
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013762 Tetrahydrofolate Dehydrogenase An enzyme of the oxidoreductase class that catalyzes the reaction 7,8-dihyrofolate and NADPH to yield 5,6,7,8-tetrahydrofolate and NADPH+, producing reduced folate for amino acid metabolism, purine ring synthesis, and the formation of deoxythymidine monophosphate. Methotrexate and other folic acid antagonists used as chemotherapeutic drugs act by inhibiting this enzyme. (Dorland, 27th ed) EC 1.5.1.3. Dihydrofolate Dehydrogenase,Dihydrofolate Reductase,Folic Acid Reductase,Acid Reductase, Folic,Dehydrogenase, Dihydrofolate,Dehydrogenase, Tetrahydrofolate,Reductase, Dihydrofolate,Reductase, Folic Acid
D045363 Pneumocystis carinii The prototype species of PNEUMOCYSTIS infecting the laboratory rat. It was formerly called Pneumocystis carinii f. sp. carinii. Strains that infect humans and cause PNEUMOCYSTIS PNEUMONIA were originally classified as Pneumocystis jirovecii or Pneumocystis carinii f. sp. hominis. Pneumocystis carinii f. sp. carinii,Pneumocystis carinii f. sp. hominis,Pneumocystis carinii f. sp. ratti,Pneumocystis jirovecii,Pneumocystis carini,Pneumocystis jiroveci
D055672 Static Electricity The accumulation of an electric charge on a object Electrostatic,Electrostatics,Static Charge,Charge, Static,Charges, Static,Electricity, Static,Static Charges
D020128 Inhibitory Concentration 50 The concentration of a compound needed to reduce population growth of organisms, including eukaryotic cells, by 50% in vitro. Though often expressed to denote in vitro antibacterial activity, it is also used as a benchmark for cytotoxicity to eukaryotic cells in culture. IC50,Concentration 50, Inhibitory
D020134 Catalytic Domain The region of an enzyme that interacts with its substrate to cause the enzymatic reaction. Active Site,Catalytic Core,Catalytic Region,Catalytic Site,Catalytic Subunit,Reactive Site,Active Sites,Catalytic Cores,Catalytic Domains,Catalytic Regions,Catalytic Sites,Catalytic Subunits,Core, Catalytic,Cores, Catalytic,Domain, Catalytic,Domains, Catalytic,Reactive Sites,Region, Catalytic,Regions, Catalytic,Site, Active,Site, Catalytic,Site, Reactive,Sites, Active,Sites, Catalytic,Sites, Reactive,Subunit, Catalytic,Subunits, Catalytic
D021281 Quantitative Structure-Activity Relationship A quantitative prediction of the biological, ecotoxicological or pharmaceutical activity of a molecule. It is based upon structure and activity information gathered from a series of similar compounds. Structure Activity Relationship, Quantitative,3D-QSAR,QSAR,QSPR Modeling,Quantitative Structure Property Relationship,3D QSAR,3D-QSARs,Modeling, QSPR,Quantitative Structure Activity Relationship,Quantitative Structure-Activity Relationships,Relationship, Quantitative Structure-Activity,Relationships, Quantitative Structure-Activity,Structure-Activity Relationship, Quantitative,Structure-Activity Relationships, Quantitative

Related Publications

Osvaldo A Santos-Filho, and Delphine Forge, and Lucas V B Hoelz, and Guilherme B L de Freitas, and Thiago O Marinho, and Jocley Q Araújo, and Magaly G Albuquerque, and Ricardo B de Alencastro, and Nubia Boechat
March 2005, Journal of medicinal chemistry,
Osvaldo A Santos-Filho, and Delphine Forge, and Lucas V B Hoelz, and Guilherme B L de Freitas, and Thiago O Marinho, and Jocley Q Araújo, and Magaly G Albuquerque, and Ricardo B de Alencastro, and Nubia Boechat
January 2015, Combinatorial chemistry & high throughput screening,
Osvaldo A Santos-Filho, and Delphine Forge, and Lucas V B Hoelz, and Guilherme B L de Freitas, and Thiago O Marinho, and Jocley Q Araújo, and Magaly G Albuquerque, and Ricardo B de Alencastro, and Nubia Boechat
July 2002, Bioorganic & medicinal chemistry,
Osvaldo A Santos-Filho, and Delphine Forge, and Lucas V B Hoelz, and Guilherme B L de Freitas, and Thiago O Marinho, and Jocley Q Araújo, and Magaly G Albuquerque, and Ricardo B de Alencastro, and Nubia Boechat
July 1995, Journal of medicinal chemistry,
Osvaldo A Santos-Filho, and Delphine Forge, and Lucas V B Hoelz, and Guilherme B L de Freitas, and Thiago O Marinho, and Jocley Q Araújo, and Magaly G Albuquerque, and Ricardo B de Alencastro, and Nubia Boechat
January 2014, Current computer-aided drug design,
Osvaldo A Santos-Filho, and Delphine Forge, and Lucas V B Hoelz, and Guilherme B L de Freitas, and Thiago O Marinho, and Jocley Q Araújo, and Magaly G Albuquerque, and Ricardo B de Alencastro, and Nubia Boechat
May 2004, Archives of pharmacal research,
Osvaldo A Santos-Filho, and Delphine Forge, and Lucas V B Hoelz, and Guilherme B L de Freitas, and Thiago O Marinho, and Jocley Q Araújo, and Magaly G Albuquerque, and Ricardo B de Alencastro, and Nubia Boechat
February 2009, Journal of enzyme inhibition and medicinal chemistry,
Osvaldo A Santos-Filho, and Delphine Forge, and Lucas V B Hoelz, and Guilherme B L de Freitas, and Thiago O Marinho, and Jocley Q Araújo, and Magaly G Albuquerque, and Ricardo B de Alencastro, and Nubia Boechat
September 2010, European journal of medicinal chemistry,
Osvaldo A Santos-Filho, and Delphine Forge, and Lucas V B Hoelz, and Guilherme B L de Freitas, and Thiago O Marinho, and Jocley Q Araújo, and Magaly G Albuquerque, and Ricardo B de Alencastro, and Nubia Boechat
March 2006, Bioorganic & medicinal chemistry,
Osvaldo A Santos-Filho, and Delphine Forge, and Lucas V B Hoelz, and Guilherme B L de Freitas, and Thiago O Marinho, and Jocley Q Araújo, and Magaly G Albuquerque, and Ricardo B de Alencastro, and Nubia Boechat
November 2010, European journal of medicinal chemistry,
Copied contents to your clipboard!